Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis (CF) after terminating a phase 1/2 trial. | Boehringer Ingelheim is discarding an inhaled gene therapy ...

Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.

PDE6A-associated RP, a rare form of inherited retinal disease (IRD), is characterized by nyctalopia, visual field defects, and significant loss of visual acuity (VA). The disease primarily affects the ...

Krystal is leveraging a validated, redosable platform with high margins, profitability, and multiple blockbuster catalysts in CF and NK. Read why KRYS is a Buy.

And the presence of the Barcelona Science Park, which is the first science park in Spain that is home to three research institutes and more than 70 companies, make the city a viable location for ...

Each year, the world's leading climate scientists evaluate the most critical evidence on how our planet is changing. Their ...

Wilding Gold Project (~5,000m planned): Initial field program consisting of ~250 percussion drill holes (basal till and ...

As AI content pollutes the web, a new attack vector opens in the battleground for cultural consensus. Research led by a Korean search company argues that as AI-generated pages encroach into search ...

Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene ...

Server hardware and software co-design for a secure, efficient cloud.

RISC-V’s expanding role in AI is not a rejection of incumbent architectures, which continue to deliver performance and compatibility across a wide range of systems. It reflects a shift in engineering ...

Popular investor Cathie Wood sold shares of software company Unity Software (U). Wood’s investment machine, Ark Invest (ARKK) ...